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Abstract 
Edelfosine is the prototype molecule of a family of anticancer drugs collectively 
known as synthetic alkyl-lysophospholipids. This drug holds promise as a selective 
antitumor agent, and a number of preclinical assays are in progress. In this study, we 
observe the accumulation of edelfosine in brain tissue after its oral administration in 
Compritol® and Precirol® lipid nanoparticles (LN). The high accumulation of 
edelfosine in brain was due to the inhibition of P-glycoprotein by Tween® 80, as 
verified using a P-glycoprotein drug interaction assay. Moreover, these LN were 
tested in vitro against the C6 glioma cell line, which was later employed to establish 
an in vivo xenograft mouse model of glioma. In vitro studies revealed that 
edelfosine-loaded LN induced an antiproliferative effect in C6 glioma cell line. In 
addition, in vivo oral administration of drug-loaded LN in NMRI nude mice bearing 
a C6 glioma xenograft tumor induced a highly significant reduction in tumor growth 
(p<0.01) fourteen days after the beginning of the treatment. Our results showed that 
Tween® 80 coated Compritol® and Precirol® LN can effectively inhibit the growth of 
C6 glioma cells in vitro and suggest that edelfosine-loaded LN represent an attractive 
option for the enhancement of antitumor activity on brain tumors in vivo.  
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1. Introduction 
Brain targeting has posed a great challenge throughout the history of therapeutics. 
Drug delivery to the brain is rigorously controlled by the blood brain barrier (BBB), 
which represents an overwhelming obstacle for many essential drugs including 
cytotoxics, antibiotics or central nervous system (CNS) active drugs [1]. The BBB is the 
homeostatic mechanism of defense of the brain against toxic molecules and pathogens. 
This exclusive membrane is formed by special endothelial cells sealed with tight 
junctions, which hamper the way into the brain from the bloodstream of many 
compounds that might be of therapeutic value in the treatment of a great assortment of 
pathologies [2, 3]. These issues, along with poor knowledge regarding the physiology of 
the CNS, have been the main limiting factors in the development of effective drugs and 
appropriate drug delivery systems (DDS) for brain targeting [1, 4-7]. In order for a drug 
to reach a target within the brain, some drawbacks that hinder its way must be taken into 
account. Among other factors, the drug must overcome the weak permeability of the 
BBB separating the blood vessels from the cerebral parenchyma [8] or the BBB active 
drug efflux transporters that are widely present in the cerebral endothelium and play an 
important role in the efflux mechanism of a wide variety of drugs [9].  
Gliomas are the most common primary brain tumors [10], glioblastoma multiforme 
being the most aggressive subtype. The prognosis for patients with glioblastoma is poor, 
with a median survival of less than a year. The failure of chemotherapy in glioma 
patients is often due to the development of resistance by tumor cells and the difficulty of 
ensuring that drugs cross the BBB. Multidrug resistance (MDR) effect is due to the 
overexpression of membrane-bound proteins that efflux drugs from the cells, resulting 
in decreased intracellular drug concentration [11]. These drug efflux proteins are 
expressed not only in the BBB but also in brain glioma cells [12, 13]. Therefore, these 
proteins restrain the transport of the drug across the BBB, and decrease intracellular 
drug concentrations inside the brain gliomas via efflux. 
Lipid nanoparticles (LN) have arisen in the last ten years as promising colloidal 
systems for the delivery of drugs to several diseases of the central nervous system, 
including tumors, as they are able to bypass the drawbacks mentioned above [14-16].  
In a previous study we showed that the alkyl-lysophospholipidic antitumor drug 
edelfosine presents a wide distribution through the organism after multiple oral 
administration of the drug in solution, presenting a higher affinity for tumor tissue as 
well as kidney and intestine, and showing very low absorption after single oral 
administrations [17]. Conversely, after a single oral administration of edelfosine-loaded 
LN, the drug was absorbed in the gastrointestinal tract and had high concentrations in 
plasma (Estella-Hermoso de Mendoza et al., submitted). Unlike different polymeric or 
liposomal systems, these LN are obtained by a solvent-free process and are physico-
chemically stable [18]. Besides, the Tween® 80 included within the LN shell inhibits the 
P-gp efflux pump [19, 20]. 
The objective of the present study was to evaluate the possibility of brain targeting 
with LN after their administration by the oral route and to assess their efficacy, both in 
vitro against a rat glioma cell line and in vivo in a glioma-bearing xenograft mouse 
animal model.  
 
2. Materials and Methods 
2.1 Chemicals  
Edelfosine was from APOINTECH (Salamanca, Spain). Compritol® 888 ATO and 
Precirol® ATO 5 were a gift from Gattefossé (Lyon, France). Tween® 80 was obtained 
from Roig Farma (Barcelona, Spain). 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl 
 3
tetrazolium bromide) (MTT), Platelet Activating Factor (PAF) and PBS (10 mM 
phosphate, 0.9 % NaCl) were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Chloroform was purchased from Panreac (Madrid, Spain) and methanol was obtained 
from Merck (Barcelona, Spain). All solvents employed for the analysis were of 
analytical grade. C6 (rat glioma) cells were purchased from ATCC (American Type 
Culture Collection, Manassas, VA, USA). Dubelcco's modified Eagle's medium 
(DMEM), heat-inactivated fetal bovine serum (FBS), trypsin–EDTA and penicillin–
streptomycin mixtures were from Gibco® BRL (Carlsbad, CA, USA). Ultra-purified 
water was used throughout and all other chemicals were of analytical grade. 
 
2.2 Preparation and characterization of LN incorporating edelfosine  
LN were prepared by the hot homogenization method consisting of high shear 
homogenization and ultrasonication. Briefly, the lipid phase comprised 300 mg of either 
Compritol® 888 ATO or Precirol® ATO 5 along with 15 mg of edelfosine, while the 
aqueous phase consisted of 10 mL of a 2 % Tween® 80 aqueous solution. The aqueous 
phase was heated at 75 ºC, in the case of Compritol® 888 ATO, or 60 ºC, in the case of 
Precirol® ATO 5 (5 ºC above the melting point of the lipid) and added to the melted 
lipid phase at the same temperature. This temperature was maintained during the 
complete process of the nanoparticle formulation. The mixture was dispersed with the 
help of a MicrosonTM ultrasonic cell disruptor (NY, USA) for 1 minute at an effective 
power of 10 W. The preformed emulsion was then homogenized in an Ultraturrax® 
(IKA-Werke, Germany) for 1 minute at 24,000 rpm and sonicated again with the 
MicrosonTM ultrasonic cell disruptor (NY, USA) for 1 minute at 10 W. The nanoparticle 
suspension was cooled in an ice bath and washed twice with filtered water by 
diafiltration with Amicon Ultra–15 filters of 10,000 dalton molecular weight cut-off 
membrane (Millipore®, Cork, Ireland) (4,000 × g, 30 min) to remove the excess of 
surfactant and non-incorporated drug. Nanoparticles were then resuspended in 10 % 
trehalose solution and kept at -80 ºC for freeze-drying. These frozen LN suspensions 
were introduced into the freeze-dryer, kept at -50 ºC. Once inside the freeze-drier, a 
slow temperature rising process was performed up to 5 ºC, for the sublimation of the 
solvent. From this point on, temperature was raised to room temperature to evaporate 
the residual molecules of water. The whole process takes place at reduced pressure 
(12·10-3 mbar). 
Particle size and distribution of the nanoparticles were measured by photon 
correlation spectroscopy (PCS) using a Zetasizer Nano (Malvern Instruments, UK). 
Each sample was diluted with distilled water until the appropriate concentration of 
particles was achieved to avoid multiscattering events. The homogenous suspension 
obtained was examined to determine the mean volume diameter, size distribution and 
polydispersity. All measurements were done in triplicate. The surface charge was 
determined by measuring the zeta potential of LN based on the Smoluchowski equation, 
using the same equipment.  
Edelfosine loading was quantified by an ultra high-performance liquid 
chromatography tandem mass spectrometry (UHPLC-MS/MS) method previously 
validated [21]. A sample of 10 mg of lyophilized nanoparticles was dissolved in 1 ml of 
chloroform and 10 μL of the internal standard PAF (0.2 mg/mL) were then spiked to the 
samples. Finally, 3 mL of methanol were added to the mixture. This solution was vortex 
mixed for 1 min at room temperature and centrifuged at 20,000 × g for 10 min. 
Eventually, 2 μL aliquots of the supernatant were injected into the chromatographic 
system. 
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2.3 P-glycoprotein inhibition experiments  
To test the ability of the LN to modulate ATPase activity of membrane located P-gp 
[22], drug loaded LN made of both lipids were tested and compared to drug loaded LN 
prepared without Tween® 80 with the P-gp drug interaction assay kit (SPIbio®, Massy, 
France). Briefly, this assay is based on the study of modulation of basal or induced 
ATPase activity from enriched P-gp membrane vesicle preparation. P-gp ATPase 
activity is measured by a spectrophotometric method based on continuous monitoring of 
ADP formation, in the vesicle suspension medium.  
LN without Tween® 80 were prepared like the regular LN, replacing the 10 mL of a 
2 % Tween® 80 aqueous solution by 10 mL of water. 
 
2.4 Cell growth inhibition studies 
The cytotoxicity of edelfosine-loaded LN against C6 rat glioma cells was measured 
by MTT assay. Tumor cells were maintained in culture in DMEM supplemented with 
10 % heat-inactivated FBS, 100 units/mL penicillin and 100 mg/mL streptomycin, at 37 
ºC in a humid atmosphere containing 5 % CO2. The cells were seeded in a 96-well plate 
at a density of 2000 cells per well, and incubated for 24 h. The medium was then 
replaced with increasing concentrations of free edelfosine, drug-loaded LN (edelfosine 
concentrations of 0.1, 1, 5, 10, 15, 20, 25, 30, 40, 50 and 70 μg/ml) and drug-free LN 
(lipid concentration of 0.5 mg/ml, corresponding to an edelfosine concentration of 70 
μg/mL). Incubation was continued as above for 72 h. All media were then removed and 
100 μL of MTT solution (0.5 mg/mL in DMEM) were added to the wells. The cells 
were incubated for 3 h. MTT was removed and DMSO was added to dissolve the 
formazan crystals [23]. The optical density at 570 nm was determined using a BioRad 
microplate reader. Untreated cells were taken as control with 100 % viability and cells 
without addition of MTT were used as blank to calibrate the spectrophotometer to zero 
absorbance. Triton X-100 1 % was used as positive control of cytotoxicity. All 
experiments were performed in triplicate. 
 
2.5 Animal studies 
All animal studies had previous approval from the Animal Care and Ethics 
Committee of the University of Navarra and the Université Catholique de Louvain. For 
biodistribution studies, BALB/c mice (20 g) were obtained from Harlan Interfauna 
Ibérica S.L. (Barcelona, Spain). For efficacy studies, NMRI mice (Janvier, Genest St 
Isle, France) were employed. Animals received a standard diet and water ad libitum. 
Freeze dried formulations were resuspended in PBS by 1 minute vortexing (JP Selecta, 
Barcelona, Spain) followed by ultrasound bath (JP Selecta, Barcelona, Spain) for 5 
minutes prior to administration. 
 
2.5.1 Biodistribution studies after oral administration 
A single oral administration of edelfosine-loaded Compritol® or Precirol® LN was 
given to two BALB/c mice groups (edelfosine concentration of 50 mg/kg, n=8 per 
group). The endpoint of the experiment was taken as the day after the concentration of 
edelfosine in plasma reached 0.5 μg/mL (168 h for Compritol® and 216 h for Precirol® 
group). At this time point, blood was collected in EDTA surface-coated tubes and then 
centrifuged at 2,000 × g for 10 min (4 ºC) to collect plasma (100 μL). After sacrifice by 
cervical dislocation, brain, liver, kidneys and intestine were collected and weighed. 
Tissues were homogenized in 1 mL of PBS pH=7.4 using a Mini-bead Beater (BioSpect 
Products, Inc., Bartelsville, Oklahoma, USA) and centrifuged at 10,000 × g for 10 min. 
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All plasma and tissue supernatants were then collected and stored at -80 ºC until 
UHPLC-MS/MS analysis was performed [21]. 
 
2.5.2 In vivo tumor growth inhibition study 
Eight-week NMRI mice were subcutaneously inoculated into the back right flank 
with 1 x 105 C6 cells in 100 μL of DMEM. The effect of the different treatments on the 
growth of C6 was assessed by the measurement of the diameter of the tumors with an 
electronic caliper every three days using the following equation: V=D·d2/2, where D and 
d correspond to the longest and shortest diameter of the tumor, respectively. Treatments 
were initiated when tumors reached 6.0 ± 0.5 mm in diameter. Mice were then divided 
into six groups (9 mice per group): group 1: PBS; group 2: edelfosine solution (30 
mg/kg; dissolved in PBS); group 3: edelfosine-loaded Compritol® 888 ATO 
nanoparticles (edelfosine concentration of 30 mg/kg); group 4: edelfosine-loaded 
Precirol® ATO 5 nanoparticles (edelfosine concentration of 30 mg/kg); group 5: blank 
Compritol® 888 ATO nanoparticles (10 mg/mL lipid concentration); and group 6: blank 
Precirol® ATO 5 nanoparticles (10 mg/mL lipid concentration). The treatments were 
administered by oral gavage every three days. Mice were sacrificed when their tumor 
diameter reached 18.0 ± 0.5 mm (30-fold increase in size). 
 
2.6 Statistical analysis 
Differences in P-gp inhibition studies were measured by Mann Whitney test, while 
mean values of the tumor sizes of all groups were analyzed by Student’s t test using 
Social Package of Statistical Sciences (SPSS). IC50 values were calculated with 
GraphPad Prism 5 software using the sigmoidal dose-response function with variable 
Hill slope. A value of p < 0.05 was considered to be statistically significant. 
 
3. Results and discussion 
3.1 Characterization of edelfosine loaded lipid nanoparticles 
The nanoparticles developed showed moderate edelfosine loading (18.5 and 15 μg 
edelfosine/mg formulation for Compritol® and Precirol®, respectively, corresponding to 
an encapsulation efficiency of 85 %). The average diameter was 111.2 ± 3.1 nm 
(Compritol® LN) and 105.5 ± 2.5 nm (Precirol® LN), with a PDI below 0.3 in all cases, 
indicating that LN were homogeneous in size (Table I).  
 
Table I. Physicochemical characteristics of the developed LN (mean ± SD).
 
LN Size (nm) PDI ζ Potential (mV) %EE 
Drug loading (μg 
edelfosine/mg form.) 
Drug-free 
Compritol® LN 132.8 ± 5.5 0.269 ± 0.033 -30.3 ± 1.9 -- -- 
Drug-loaded 
Compritol® LN 111.2 ± 3.1 0.271 ± 0.020 -20.6 ± 2.1 85.53 ± 6.92 18.49 ± 2.77 
Drug-free 
Precirol® LN 118.9 ± 2.3 0.246 ± 0.029 -30.1 ± 1.1 -- -- 
Drug-loaded 
Precirol® LN 105.4 ± 2.5 0.227 ± 0.015 -21.6 ± 3.1 84.62 ± 4.98 15.31 ± 3.29 
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Figure 1 represents the size distribution of representative formulations of both 
Compritol® and Precirol® LN. Zeta potential was negative in all cases, around -21 mV 
for both types of drug-loaded LN, while drug-free LN presented zeta potential values of 
-30 mV, meaning that some drug was located on the surface of the nanoparticles, being 
responsible for the decrease in the zeta potential by leaving less room for Tween® 80 to 
accommodate on the surface of the LN. 
 
Figure 1. Representative size distribution of edelfosine-loaded A) Precirol® and B) Compritol® LN 
formulations. 
 
 
3.2 Biodistribution study 
In a previous study, the biodistribution patterns of orally administered free 
edelfosine revealed that the drug was widely scattered in many organs, but only a small 
amount was found in the brain [17]. However, when edelfosine is orally administered in 
LN, the biodistribution pattern is altered and accumulation of drug in brain is increased. 
This change in the biodistribution pattern supports the existence of intact LN in plasma, 
which later will allow the drug cross the blood brain barrier. Besides, it has been 
described by Olbrich and Müller [24] that some stabilizers, such as Poloxamer 407 or 
Tween 80, distinctly slow down the degradation velocity of the LN, as they provide 
sterically stabilizing layers of different thicknesses which hamper the anchoring of 
lipases/colipases and consequently, decrease the degradation velocity. This gives time 
for the LN to be absorbed. Figure 2 shows how, after the oral administration of 
edelfosine-loaded Compritol® and Precirol® LN (168 h and 216 h, respectively), 
edelfosine presents high tissue/plasma ratios of 4.5 and 12.4 for Precirol® and 
Compritol® LN, respectively, indicating higher accumulation in mouse brain when 
edelfosine is administered encapsulated in LN. These values are much higher compared 
to those when edelfosine was administered in solution (tissue/plasma ratio < 0.5) [17].  
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Figure 2. Tissue/plasma concentration ratios of edelfosine after a single oral dose of edelfosine-loaded 
Compritol® and Precirol® LN to BALB/c mice (n=8 per group, mean ± SD).  
  
3.3 In vitro studies 
The accumulation of drug in brain tissue when administered into LN is probably 
due to the inhibition of P-gp by the nanoparticles. To confirm this, a P-gp drug 
interaction in vitro assay was performed, in which Compritol® and Precirol® LN were 
tested against P-gp containing membrane vesicles. The P-gp inhibition in an in vitro test 
system was observed to be particle size and concentration independent. Figure 3 shows 
how Tween® 80 coated Precirol® and Compritol® LN (150 μg/mL of edelfosine) 
formulations were found to be more efficient in inhibiting P-gp, significantly decreasing 
P-gp relative activity compared to that of the baseline activity. On the other hand, LN 
prepared without Tween® 80 (150 μg/mL of edelfosine) did not decrease the relative 
activity of P-gp. Furthermore, lower LN concentrations (15 μg/mL and 1.5 μg/mL of 
edelfosine loaded LN) were observed still to be able to lower the P-gp activity. All these 
data confirm that Tween® 80 is an essential component in LN for inhibition of the P-gp.  
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Figure 3. P-gp inhibition experiments with the SPIbio® test system for the different LN formulations and 
concentrations of edelfosine (1.5, 15 and 150 μg/mL). Comparable standards are given by the baseline 
activity of the test system with additional results from P-gp inhibitor vinblastine. The baseline activity of 
the test system itself was taken as 1.0 value. (n=4, mean ± SD) *p<0.05 levels by Mann Whitney’s U test 
compared with baseline ATPase activity of P-gp. 
 
Several studies have recently demonstrated that pharmaceutical excipients which 
are largely used as inert vehicles in drug formulations, like Cremophor-EL, Triton X-
100 and Tween® 80 are emerging as a special class of P-gp inhibitors [25]. Some of 
these may even disrupt the function of P-gp and thus enhance the absorption of the 
drugs that are substrates of P-gp across different barriers. On the other hand, the 
mechanism by which nanoparticles cross the BBB is still uncertain but depending on 
the LN composition, the P-gp efflux pump inhibition can be conferred to the LN. For 
instance, Tween® 80 produces changes of membrane fluidity in the cells [26]. More 
concretely, it contains oxyethylene groups that may change the fluidity of the polar head 
group regions of cell membranes [27]. The disturbance of this environment might cause 
changes in secondary and tertiary structure of P-gp, leading to the loss of its function. 
Besides, the effect of Tween® 80 may also result in a negative regulation of the ATPase 
activity of the P-gp [9, 14].  
In addition to this, another accepted way by which Tween® 80 coated LN are able 
to cross the BBB implies the adsorption of apolipoproteins (especially ApoE) onto the 
surface of the LN, so that after being recognized by the low-density lipoprotein (LDL) 
receptors present in the BBB, they are internalized [28-30]. The adsorption of 
apolipoproteins onto the nanoparticle surface, along with the solubilization of 
endothelial cell membrane lipids and membrane fluidization due to surfactant effects of 
polysorbates, is thought to be responsible for LN uptake in the brain after their adhesion 
to the endothelial cells of the blood brain barrier [28, 30]. After confirming that LN are 
able to get through the BBB by means of P-gp inhibition and assuming ApoE 
adsorption, we aimed to assess the cytotoxicity of edelfosine-loaded LN, and their 
tumor cell killing activity was determined against the C6 rat glioma cell line by MTT 
assay. Cytotoxicity was assessed by the comparison of IC50 values of free edelfosine, 
edelfosine-loaded LN and drug-free LN. The results of the cytotoxicity studies indicate 
that edelfosine-loaded Compritol® and Precirol® LN significantly reduced IC50 values in 
a P-gp overexpressing glioma cell line over free drug. Free edelfosine showed a very 
high IC50 value of 27.5 μg/mL (55 μM), suggesting resistance of this cell line to the 
drug after 72 h (Figure 4) and, indeed, the disruption of tumor cell membranes, is due to 
a detergent effect of the molecule, rather than apoptotic, as edelfosine presents an 
amphiphilic structure [31, 32].  
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Figure 4. Viability study of C6 rat glioma cell line 72 h after the treatment with increasing  
concentrations of (A) free edelfosine and drug loaded (B) Compritol® and (C) Precirol® LN (n=6, mean 
log Concentration ± SD). 
 
This low drug effectiveness is mainly ascribed to enhanced active efflux of the drug 
out of the cell, for which P-gp is responsible [33]. However, when edelfosine was 
incorporated into either Compritol® or Precirol® LN, the IC50 value 72 h after the 
treatment decreased dramatically to 4.3 μg/mL (8.6 μM) and 4.7 μg/mL (9.4 μM), 
respectively. The intense decrease in the IC50 value is probably due to the small size of 
LN, making possible an intracellular uptake, and the P-gp inhibiting properties already 
described, since Tween® 80 can inhibit P-gp related drug transport [19, 20]. Thus, the 
adjuvant effect of Tween® 80 seems to be imperative for high intracellular drug 
concentration maintenance. Edelfosine-free LN vehicles did not cause cytotoxicity 
against C6 cell line since the percentage of cell survival was above 85% (data not 
shown). The current study therefore suggests that there might be at least two major 
reasons for enhanced cytotoxicity of edelfosine-loaded LN in P-gp-mediated resistant 
cells: (a) a possible increased extent of drug uptake by endocytosis of nanoparticles, 
which helps to partially bypass P-gp; and (b) a decreased efflux rate of drug through 
inhibition of P-gp function caused by Tween® 80, a component of nanoparticles. They 
both increase intracellular drug concentrations, which is the key to overcoming 
transporter-mediated resistance [19]. 
 
3.4 In vivo tumor growth inhibition study 
After the in vitro effectiveness of the LN had been confirmed, we evaluated their 
efficacy in an in vivo xenograft C6 rat glioma bearing mouse model. For that reason, 
xenograft C6 glioma bearing mice were treated with oral administrations of 30 mg/kg of 
edelfosine solution and edelfosine-loaded Compritol® and Precirol® LN every 3 days 
for 14 days. Tumor growth was followed as a function of time after treatment (Figure 
5). In addition, changes in mean body weight were determined as a measure of drug 
induced toxicity. Regardless of the type of LN used, the therapeutic activity of the 
 10
edelfosine-loaded LN formulations was significantly higher than the edelfosine solution 
administered at the same dose. Treatments did not show visible toxicity, as a decrease in 
body weight was not observed in any group (data not shown).  
 
 
Figure 5. Evolution of tumor growth of xenograft C6 rat glioma implanted in mice, expressed as fold-
increase ratio compared to tumor initial size, after treatments with PBS, free edelfosine (30 mg/kg bw), 
drug loaded LN (30 mg/kg bw) and drug-unloaded LN every three days over the oral route (n=9 per 
group, mean ± SD). Statistical analysis by Student’s t test. 
 
Regarding efficacy, significant differences were observed in tumor regression at 
day 6, after the third oral dose of edelfosine-loaded LN (Figure 5), compared to the oral 
administration of the edelfosine solution and the drug-unloaded LN, which did not have 
any effect on the tumor growth. The tumor burden of edelfosine-loaded LN treated mice 
was significantly smaller compared with control (PBS), free drug or drug-unloaded LN 
treated mice. The hypothesis for the mechanism of action of these LN against this 
xenograft glioma can be attributed to two main issues. First, the inhibition of the P-gp 
by Tween® 80 by the oxyethylene groups that it contains in its molecular structure, 
which may alter the fluidity of the membrane leading to P-gp disfunction [27]; and 
second, the release of the drug from the nanoparticles once these are internalized in the 
cell. The combination of these two effects could be responsible for the high intracellular 
accumulation of the drug in the tumor, preventing its removal from the cytosol by efflux 
pump proteins (P-gp).As a result, the consequent increase in drug concentration would 
permit the onset of tumor cell death.  
 
 
4. Conclusions   
In this article, a high accumulation of edelfosine was found in brain tissue when 
administered in LN, suggesting that these nanocarriers might be useful for the delivery 
of edelfosine to the brain. Moreover, in vitro studies against C6 cell line showed that 
edelfosine loaded Compritol® and Precirol® LN were able to revert the resistance of the 
cell to the drug, due to the inhibition of P-gp by Tween® 80. The oral administration of 
edelfosine-loaded LN to mice every three days decreased tumor growth significantly, 
when compared to the administration of the same dose of the free drug.  
In conclusion, these nanocarriers show promise as a potential effective therapeutic 
agent in order to treat neoplastic diseases located in brain tissue. 
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Figure Legends 
 
Figure 1. Representative size distribution of edelfosine-loaded A) Precirol® and B) 
Compritol® LN formulations. 
 
Figure 2. Tissue/plasma concentration ratios of edelfosine after a single oral dose of 
edelfosine-loaded Compritol® and Precirol® LN to BALB/c mice (n=8 per group, mean 
± SD).  
 
Figure 3. P-gp inhibition experiments with the SPIbio® test system for the different LN 
formulations and concentrations of edelfosine (1.5, 15 and 150 μg/mL). Comparable 
standards are given by the baseline activity of the test system with additional results 
from P-gp inhibitor vinblastine. The baseline activity of the test system itself was taken 
as 1.0 value. (n=4, mean ± SD) *p<0.05 levels by Mann Whitney’s U test compared 
with baseline ATPase activity of P-gp. 
 
Figure 4. Viability study of C6 rat glioma cell line 72 h after the treatment with 
increasing concentrations of (A) free edelfosine and drug loaded (B) Compritol® and 
(C) Precirol® LN (n=6, mean log Concentration ± SD). 
 
Figure 5. Evolution of tumor growth of C6 rat glioma implanted in mice, expressed as 
fold-increase ratio compared to tumor initial size, after treatments with PBS, free 
edelfosine (30 mg/kg bw), drug loaded LN (30 mg/kg bw) and drug-unloaded LN every 
three days over the oral route (n=9 per group, mean ± SD). Statistical analysis by 
Student’s t test. 
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